{"nctId":"NCT00794573","briefTitle":"Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial","startDateStruct":{"date":"2009-09"},"conditions":["Acute Coronary Syndrome"],"count":302,"armGroups":[{"label":"Varenicline","type":"EXPERIMENTAL","interventionNames":["Drug: varenicline"]},{"label":"Sugar pill","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"varenicline","otherNames":["Champix (Canada)","Chantix (USA)"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Active smoker, greater than or equal to 10 cigarettes per day, on average, for the past year.\n* Age greater than or equal to 18 years.\n* Motivated to quit smoking.\n* Able to understand and to provide informed consent in English or French.\n* Likely to be available for follow-up.\n* Suffered an ACS, including myocardial infarction (MI) or unstable angina (UA) with significant coronary artery disease, and currently hospitalized or at discharge from current hospitalization.\n\nMI is defined as positive Troponin T, Troponin I, or CK-MB levels and ≥ 1 of the following:\n\n1. Ischemic symptoms (i.e. typical chest pain) for at least 20 minutes.\n2. Electrocardiogram (ECG) changes indicative of ischemia (ST-segment elevation or depression).\n3. Development of pathological Q waves on the ECG.\n\nUA with significant coronary artery disease is defined as all of the following:\n\n1. Negative Troponin T, Troponin I, or CK-MB levels;\n2. Ischemic symptoms (i.e. typical chest pain) for at least 20 minutes;\n3. ECG changes indicative of ischemia (ST-segment changes); and\n4. At least one lesion ≥ 50% on angiogram performed during the current hospitalization.\n\nExclusion Criteria:\n\n* Medical condition with a prognosis of \\< 1 year.\n* Pregnant or lactating females.\n* Reported NYHA Class or Killip III or IV at randomization.\n* Previous use of varenicline.\n* Current use of any medical therapy for smoking cessation (e.g. BuSpar, doxepin,fluoxetine, nicotine gum, nicotine patch, or bupropion).\n* History of bulimia or anorexia nervosa.\n* Diagnosis of major depression (requiring medication) in the previous 5 years or diagnosis of two or more lifetime episodes of major depression (requiring medication)\n* A total of 5 or more responses (one of which includes question 1 or 2) of \"more than half the days\" or \"nearly every day\" to the questions on the PHQ-9 questionnaire.\n* History of suicidal events (previous suicide attempt, suicidal ideation) or family history of suicide.\n* History of or current panic disorder, psychosis, bipolar disease, or dementia.\n* Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment (AST or ALT levels greater than or equal to 2 times upper limit of normal prior to admission for ACS).\n* Renal impairment with creatinine levels greater than or equal to 2 times the upper limit of normal.\n* Excessive alcohol consumption defined as greater than or equal to 14 alcoholic drinks per week.\n* Use of any illegal drugs in the past year (e.g. cocaine, heroin, opiates).\n* Use of any marijuana or other tobacco products during the study.\n* Current use of over-the-counter stimulants (e.g. ephedrine, phenylephrine) or anorectics.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"7-Day Point Prevalence Smoking Abstinence","description":"7-day point prevalence abstinence at week 24, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"PRIMARY","title":"Continuous Smoking Abstinence","description":"Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 24.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"7-Day Point Prevalence Smoking Abstinence","description":"7-day point prevalence abstinence at week 52, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Continuous Smoking Abstinence","description":"Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 52.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"7-Day Point Prevalence Smoking Abstinence","description":"7-day point prevalence abstinence at week 12, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Continuous Smoking Abstinence","description":"Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 12.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"7-Day Point Prevalence Smoking Abstinence","description":"7-day point prevalence abstinence at week 4, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Continuous Smoking Abstinence","description":"Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 4.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Reduction in Daily Cigarette Consumption by 50% or Greater","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Reduction in Daily Cigarette Consumption by 50% or Greater","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Reduction in Daily Cigarette Consumption by 50% or Greater","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Reduction in Daily Cigarette Consumption by 50% or Greater","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":151},"commonTop":["Insomnia","Nausea","Abnormal Dreams","Nightmares","Headache"]}}}